Junshi biosciences

Index
Globenewswire

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Globenewswire

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

Globenewswire

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

Globenewswire

Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients

Globenewswire

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

Globenewswire

Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates

Globenewswire

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

Globenewswire

Junshi Biosciences Announces Ongericimab’s sNDA Approval in China

Globenewswire

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

Globenewswire

Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

Globenewswire

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

Globenewswire

Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma

Globenewswire

Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe

Globenewswire

Junshi Biosciences Announces Toripalimab’s Approval in Australia

Globenewswire

Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab

Globenewswire

Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR

Globenewswire

Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab

Globenewswire

Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates

Globenewswire

Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma

Globenewswire

Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab

Globenewswire

Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Globenewswire

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC

Globenewswire

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer

Globenewswire

Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint

Globenewswire

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab